Immature T cell lymphomas comprise a significant portion of human lymphoid malignancies. Many of these tumors harbor recurrent chromosomal translocations and related aberrations that either activate proto-oncogenes, inactivate tumor suppressor genes, or create novel oncogenic fusion genes. Most oncogenic translocations of human immature T cell lymphomas are thought to occur via errors in the repair of DNA double strand breaks (DSBs) introduced at T cell receptor (TCR) loci during V(D)J recombination and/or general DSBs at other genomic locations. We propose to elucidate functions of the DSB response in suppression of translocations associated with T cell lymphomas and to generate novel mouse models for human T cell lymphoma. We also propose to elucidate molecular mechanisms that underlie recurrent translocations in T cell lymphomas, including how spatial proximity, DSB frequency and DNA repair pathway availability affect translocation patterns. Recurrent chromosome 14 translocations in the vicinity of the TCRa/d locus are found frequently in ATM-deficient mouse thymic lymphomas and similar translocations are found in human T cell lymphomas that have mutated ATM genes. In this regard, we find that a region 10 Mb upstream of the TCRa/d locus is highly amplified on chromosome 14 in most ATM-deficient mouse thymic lymphomas. We propose to fully investigate this recurrent translocation/amplification in ATM-deficient T cell lymphomas i) to elucidate mechanistic aspects, including potential roles of TCRa/d locus V(D)J recombination and TCRa/d enhancers (with Project 2, Harald von Boehmer), ii) to identify target oncogene(s) (with Project 5, Rick Young), and iii) to determine relevance to human T cell lymphomas (with Project 1 Tom Look). For translocations, participating loci on different chromosomes must be broken and must be in close proximity for joining. Thus we propose to test the hypothesis that frequent activation of certain proto-oncogenes via translocation to TCR loci in human, but not mouse, T cell lymphomas may reflect the relative frequency of DNA DSBs and the spatial proximity of target loci. To address this question, we will employ various approaches including 3D FISH and the generation of novel cell culture and mouse models in which DNA breaks are introduced into target T-cell oncogenes during T-cell development. We will also employ these models to test our hypothesis that ATM and its substrates (e.g., H2AX) prevent translocations resulting from aberrant V(D)J recombination by stabilizing TCR locus DSBs introduced during V(D)J recombination. Together, these studies should allow us to address long-standing questions regarding the mechanisms underlying chromosomal translocation targeting in T-ALL and other cancers.
Immature human T cell lymphomas often harbor recurrent chromosomal translocations that activate oncogenes or inactivate tumor suppressor genes. We propose to elucidate mechanisms of oncogenic translocations and molecular pathways that lead to thymic malignancies in mice and humans. Better understanding of fundamental processes that lead to thymic lymphoma, along with the novel mouse models we will generate via our proposed studies, should facilitate development of better treatments. Frequent interaction with investigators in this program will greatly enhance the accomplishment of our goals.
|Lobbardi, Riadh; Pinder, Jordan; Martinez-Pastor, Barbara et al. (2017) TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov 7:1336-1353|
|Rahman, Sunniyat; Magnussen, Michael; León, Theresa E et al. (2017) Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood 129:3221-3226|
|Winter, Georg E; Mayer, Andreas; Buckley, Dennis L et al. (2017) BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Mol Cell 67:5-18.e19|
|Li, Z; Abraham, B J; Berezovskaya, A et al. (2017) APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia 31:2057-2064|
|Abraham, Brian J; Hnisz, Denes; Weintraub, Abraham S et al. (2017) Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun 8:14385|
|Erb, Michael A; Scott, Thomas G; Li, Bin E et al. (2017) Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543:270-274|
|Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M et al. (2016) Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol 12:876-84|
|Hnisz, Denes; Weintraub, Abraham S; Day, Daniel S et al. (2016) Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science 351:1454-1458|
|Akahane, K; Sanda, T; Mansour, M R et al. (2016) HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 30:219-28|
|Tan, S H; Yam, A W Y; Lawton, L N et al. (2016) TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. Leukemia 30:959-62|
Showing the most recent 10 out of 62 publications